Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial)

American Journal of Cardiology

Volumn 115, Issue 6, 2015, Pages 790-796

  Khan, Sadiya S ^a   Campia, Umberto ^b   Chioncel, Ovidiu ^c   Zannad, Faiez ^d   Rossignol, Patrick ^d   Maggioni, Aldo P ^e   Swedberg, Karl ^f   Konstam, Marvin A ^g   Senni, Michele ^h   Nodari, Savina ⁱ   Vaduganathan, Muthiah ^j   Subacius, Haris ^a   Butler, Javed ^k   Gheorghiade, Mihai ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MedStar Cardiovascular Research Network   (United States)

^c Inst Cardiovasc Dis CC Iliescu   (ROM)

^d UNIVERSITÉ DE LORRAINE   (France)

^e ANMCO RESEARCH CENTER   (Italy)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g TUFTS MEDICAL CENTER   (United States)

^h PAPA GIOVANNI XXIII HOSPITAL   (Italy)

ⁱ UNIVERSITY OF BRESCIA   (Italy)

^j HARVARD MEDICAL SCHOOL   (United States)

^k EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; HEART EJECTION FRACTION; HEART FAILURE; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84964285896     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.12.045     Document Type: Article

References (21)

1. A. Ahmed, F. Zannad, T.E. Love, J. Tallaj, M. Gheorghiade, O.J. Ekundayo, and B. Pitt A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure Eur Heart J 28 2007 1334 1343
2. A.B. Alper, R.C. Campbell, S.D. Anker, G. Bakris, C. Wahle, T.E. Love, L.L. Hamm, M. Mujib, and A. Ahmed A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure Int J Cardiol 137 2009 1 8
3. K. Bishu, A. Deswal, H.H. Chen, M.M. LeWinter, G.D. Lewis, M.J. Semigran, B.A. Borlaug, S. McNulty, A.F. Hernandez, E. Braunwald, and M.M. Redfield Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction Am Heart J 164 2012 763 770
4. J.E. Macdonald, and A.D. Struthers What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol 43 2004 155 161
5. G.M. Felker, K.L. Lee, D.A. Bull, M.M. Redfield, L.W. Stevenson, S.R. Goldsmith, M.M. LeWinter, A. Deswal, J.L. Rouleau, E.O. Ofili, K.J. Anstrom, A.F. Hernandez, S.E. McNulty, E.J. Velazquez, A.G. Kfoury, H.H. Chen, M.M. Givertz, M.J. Semigran, B.A. Bart, A.M. Mascette, E. Braunwald, C.M. O'Connor Network NHFCR Diuretic strategies in patients with acute decompensated heart failure N Engl J Med 364 2011 797 805
6. J.E. Blair, P.S. Pang, R.W. Schrier, M. Metra, B. Traver, T. Cook, U. Campia, A. Ambrosy, J.C. Burnett Jr., L. Grinfeld, A.P. Maggioni, K. Swedberg, J.E. Udelson, F. Zannad, M.A. Konstam, and M. Gheorghiade Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial Eur Heart J 32 2011 2563 2572
7. M.I. Ahmed, O.J. Ekundayo, M. Mujib, R.C. Campbell, P.W. Sanders, B. Pitt, G.J. Perry, G. Bakris, I. Aban, T.E. Love, W.S. Aronow, and A. Ahmed Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study Int J Cardiol 144 2010 383 388
8. M. Gheorghiade, C. Orlandi, J.C. Burnett, D. Demets, L. Grinfeld, A. Maggioni, K. Swedberg, J.E. Udelson, F. Zannad, C. Zimmer, and M.A. Konstam Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: outcome study with tolvaptan (EVEREST) J Card Fail 11 2005 260 269
9. M. Gheorghiade, M.A. Konstam, J.C. Burnett Jr., L. Grinfeld, A.P. Maggioni, K. Swedberg, J.E. Udelson, F. Zannad, T. Cook, J. Ouyang, C. Zimmer, and C. Orlandi Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials JAMA 297 2007 1332 1343
10. M.A. Konstam, M. Gheorghiade, J.C. Burnett Jr., L. Grinfeld, A.P. Maggioni, K. Swedberg, J.E. Udelson, F. Zannad, T. Cook, J. Ouyang, C. Zimmer, and C. Orlandi Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial JAMA 297 2007 1319 1331
11. C.B. Bowling, B. Pitt, M.I. Ahmed, I.B. Aban, P.W. Sanders, M. Mujib, R.C. Campbell, T.E. Love, W.S. Aronow, R.M. Allman, G.L. Bakris, and A. Ahmed Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies Circ Heart Fail 3 2010 253 260
12. O.J. Ekundayo, C. Adamopoulos, M.I. Ahmed, B. Pitt, J.B. Young, J.L. Fleg, T.E. Love, X. Sui, G.J. Perry, D.S. Siscovick, G. Bakris, and A. Ahmed Oral potassium supplement use and outcomes in chronic heart failure: a propensity-matched study Int J Cardiol 141 2010 167 174
13. M. Gheorghiade, P.S. Pang, A.P. Ambrosy, G. Lan, P. Schmidt, G. Filippatos, M. Konstam, K. Swedberg, T. Cook, B. Traver, A. Maggioni, J. Burnett, L. Grinfeld, J. Udelson, and F. Zannad A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial Heart Fail Rev 17 2012 485 509
14. J.E. Sealey, and J.H. Laragh A proposed cybernetic system for sodium and potassium homeostasis: coordination of aldosterone and intrarenal physical factors Kidney Int 6 1974 281 290
15. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, and J. Wittes The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 1999 709 717
16. F. Zannad, J.J. McMurray, H. Krum, D.J. van Veldhuisen, K. Swedberg, H. Shi, J. Vincent, S.J. Pocock, B. Pitt Group E-HS Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
17. D.N. Juurlink, M.M. Mamdani, D.S. Lee, A. Kopp, P.C. Austin, A. Laupacis, and D.A. Redelmeier Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study N Engl J Med 351 2004 543 551
18. L. Wei, A.D. Struthers, T. Fahey, A.D. Watson, and T.M. Macdonald Spironolactone use and renal toxicity: population based longitudinal analysis BMJ 340 2010 1768
19. P. Rossignol, D. Dobre, J.J. McMurray, K. Swedberg, H. Krum, D.J. van Veldhuisen, H. Shi, M. Messig, J. Vincent, N. Girerd, G. Bakris, B. Pitt, and F. Zannad Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) Circ Heart Fail 7 2014 51 58
20. R.W. Schrier, and M. Gheorghiade Challenge of rehospitalizations for heart failure: potential of natriuretic doses of mineralocorticoid receptor antagonists Am Heart J 161 2011 221 223
21. B. Pitt, G. Filippatos, M. Gheorghiade, L. Kober, H. Krum, P. Ponikowski, C. Nowack, P. Kolkhof, S.Y. Kim, and F. Zannad Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease Eur J Heart Fail 14 2012 668 675